EVP-ABD-enhanced MRI to evaluate diffuse liver disease in a rat model

Area of Science:

• Magnetic Resonance Imaging (MRI)
• Hepatitis Research
• Contrast Agent Development

Background:

• Diffuse liver disease diagnosis remains challenging.
• Novel imaging techniques are needed for accurate assessment.
• Manganese-based contrast agents offer potential for enhanced MRI.

Purpose of the Study:

• To assess the feasibility of using EVP-ABD, a manganese-based MRI contrast agent, for detecting diffuse liver disease.
• To evaluate EVP-ABD's efficacy in a rat model of carbon tetrachloride (CCl4)-induced hepatitis.
• To correlate MRI findings with histological assessments of liver damage.

Main Methods:

• Hepatitis was induced in rats using intraperitoneal CCl4 administration.
• MRI scans were performed on a 3T scanner before and after EVP-ABD administration.
• Liver R1 values and changes (DeltaR1) were analyzed and correlated with CCl4 dose and histology.

Main Results:

• Liver R1 values and DeltaR1 showed significant correlation with CCl4 dose.
• Histological scores correlated significantly with CCl4 doses.
• A significant correlation was observed between histological scores and DeltaR1.

Conclusions:

• EVP-ABD-enhanced MRI can detect CCl4-induced diffuse liver disease in rats.
• The correlation between liver proton R1 post-EVP-ABD and CCl4 dose/histology supports its diagnostic potential.
• This study highlights EVP-ABD's promise as an MRI contrast agent for liver disease detection.